Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Alexander Bukreyev · UNIVERSITY OF TEXAS MED BR GALVESTON · 2021 · $758,862 — PROJECT SUMMARY/ABSTRACT The Marburg virus (MARV) and Ravn virus (RAVV), which both belong to the genus Marburgvirus of the family Filoviridae, cause the severe disease in humans, with case fatality rates up to 90%. There are no licensed vaccines against marburgviruses. Clinical trials of vaccine ca…
CHRISTOPHER A BENEDICT · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2021 · $615,063 — Summary Cytomegalovirus (CMV, a b-herpesvirus) establishes a persistent infection that is endemic in humans and mice. CMV causes acute clinical disease only if immunity is naïve or compromised, exemplifying how coevolution with its host over millennia has resulted in a largely non-pathogenic détente…
SAUL r TZIPORI · TUFTS UNIVERSITY BOSTON · 2021 · $206,250 — We seek NIH funding to develop a vaccine against cryptosporidiosis for children in LMIC. As no effective therapies exist, there is a critical need for vaccination to reduce morbidity and mortality attributed to cryptosporidiosis, which is estimated to cause diarrhea in >10 million children and kills…
Alejandro Castellanos-Gonzalez · UNIVERSITY OF TEXAS MED BR GALVESTON · 2021 · $197,500 — Project Summary/Abstract The World Health Organization reports diarrhea kills around 760,000 children under five every year. Cryptosporidium is a leading cause of diarrhea morbidity and mortality. Therefore novel treatments against this pathogen are urgently needed. The limitations of tools used to …
Clayton C Caswell · VIRGINIA POLYTECHNIC INST AND ST UNIV · 2021 · $77,739 — Project Summary Brucella spp. are bacteria that naturally infect a variety of domesticated and wild animals leading to abortions and sterility, and these bacteria are also capable of causing debilitating human infections, which often result from human exposure to infected animals and animal product…
Darrell J Irvine · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2021 · $500,599 — PI: Irvine, Darrell J. Project Summary/Abstract: Strategies to promote the magnitude and quality of T cell and antibody responses following immunization have broad relevance for the development of new prophylactic and therapeutic vaccines for the treatment of cancer and infectious diseases. Recent s…
Elana Ben-Akiva · JOHNS HOPKINS UNIVERSITY · 2021 · $39,471 — The overall goal of this project is to engineer novel biodegradable cationic polymers for intracellular delivery of nucleic acid materials to antigen presenting cells (APCs) for cancer immunotherapy applications. Immune cells are conventionally very difficult to transfect, and the most successful pl…
David Mitchell Smith · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2021 · $123,468 — Project Summary This application is a proposed renewal of Dr. Davey Smith's K24 grant entitled `Mentoring Translational Research in HIV'. This grant supported the training of over 30 trainees and 80 publications to date. While significant progress in HIV research continues to be made, it is not like…
Shioko Kimura · DIVISION OF BASIC SCIENCES - NCI · 2021 · $686,816 — Previously we found that SCGB3A2 is a lipopolysaccharide (LPS) binding protein, and SCGB3A2-LPS complex binds to a cell surface receptor syndecan-1 (SDC1), and endocytosed cytosolic LPS binds to caspase-11 and activates the non-canonical inflammasome pathway, resulting in pyroptosis. Mouse Lewis lun…
Bernard Moss · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $369,339 — Poxviruses encode enzymes and factors needed for transcription and replication of their genomes within the cytoplasm of infected cells. Vaccinia virus, the prototypic member of the poxvirus family, provides a unique system for combining biochemical and genetic approaches for investigating mechanisms…
Barney Graham · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $1,604,857 — While the outbreak of ZIKV in the Americas has subsided, there is an ongoing risk of congenital Zika syndrome in babies born to mothers exposed to ZIKV during pregnancy. There is no licensed vaccine or treatment to combat ZIKV infection. Because of the urgent need for a ZIKV vaccine, and a finite ti…
Barton F. Haynes · DUKE UNIVERSITY · 2021 · $260,308 — The Administrative Core will coordinate the scientific and administrative activities of this IPCAVD Program, ensuring that the Projects and Cores function well together. In particular, it will be responsible for managing the program's financial management, program management, and coordinating Projec…
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2021 · $1,264,760 — The elicitation of cross-neutralizing or broadly neutralizing Abs (bNAbs) to diverse HIV strains by Env vaccination remains a high priority for a broadly efficacious vaccine. The elicitation of bNAbs against conserved Env determinants remains elusive; however, the recent isolation of bNAbs to the fu…
Barton F. Haynes · DUKE UNIVERSITY · 2021 · $96,745 — Vaccine trials in non-human primates challenged with R5, tier 2 SHIVs have shown protection in the presence of high levels of non-neutralizing antibodies (NNAbs), and one of the 5 Phase IIb HIV-1 vaccine efficacy trials using alum (ALVAC/AIDSVAX in RV144) showed an estimated vaccine efficacy of 31%,…
STANLEY FIELDS · UNIVERSITY OF WASHINGTON · 2021 · $312,823 — Project Summary In TR&D 1, we develop approaches to make complex changes to cells, and we generate biosensors to report on the effects of some of these changes. In the first aim, we establish strategies to rapidly and combinatorially up- or down-regulate a set of genes in a common pathway in order t…
Sallie R. Permar · WEILL MEDICAL COLL OF CORNELL UNIV · 2021 · $242,755 — ABSTRACT – Project 1 There is a critical need to protect adolescents and young adults from HIV infection through the development of an early life vaccine strategy that elicits protective immunity prior to sexual debut. However, to date, efforts to develop a vaccine that can elicit protective broadly…
Kai W Wucherpfennig · BRIGHAM AND WOMEN'S HOSPITAL · 2021 · $359,181 — Abstract T cells are central effector cells of protective anti-tumor immunity, but little is currently known about these important immune cells in human GBM. We have generated single-cell RNA-seq data on tumor-infiltrating T cell populations from GBM patients at initial diagnosis or relapse. We used…
Sallie R. Permar · WEILL MEDICAL COLL OF CORNELL UNIV · 2021 · $339,713 — ABSTRACT – Nonhuman Primate Core (NHP Core/ Core 1) The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can achieve long-term protective immunity, similar to that of vaccines that have nearly eliminated other global pathogens. HIV acquisition risk begins in ute…
Brent W Segelke · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · 2021 · $230,478 — PROJECT SUMMARY/ABSTRACT Project Title: Scientific Core 2: Protein Expression and Characterization Core We will establish and operate a protein expression and characterization core that serves the Cooperative Research Center for Nano-Scaffold Vaccines Against Chlamydia trachomatis (Ct) by providing …
Gunilla Karlsson Hedestam · SCRIPPS RESEARCH INSTITUTE, THE · 2021 · $387,441 — Summary Circulating (tier 2) HIV-1 variants are highly resistant to antibody-mediated neutralization, making broadly effective vaccine design a major challenge. Encouragingly, work in our previous HIVRAD program demonstrated that Ab responses capable of cross-neutralizing multiple heterologous tier …